ICU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SeaStar Medical Holding Corp (ICU) is not a strong buy for a beginner, long-term investor at this time. While the company has shown significant revenue growth, its financial performance is weighed down by substantial net income losses and declining EPS. Additionally, there are no strong technical or proprietary trading signals supporting an immediate buy decision. Analysts have lowered the price target, and there are no significant positive catalysts or trading trends to suggest a strong upward movement in the near term.
The MACD is slightly positive but contracting, RSI is neutral at 60.193, and moving averages are converging, indicating no clear trend. The stock's key support and resistance levels suggest limited immediate upside potential, with resistance at 4.729 and support at 3.537.
The company reported a significant revenue increase of 526.87% YoY in Q4 2025, and positive clinical experience from its QUELIMMUNE therapy was published in a peer-reviewed journal.
Net income dropped by -34.28% YoY, EPS declined by -91.08% YoY, and gross margin decreased slightly. Analysts have lowered the price target from $10 to $6, citing share dilution.
In Q4 2025, revenue increased significantly to $420,000 (up 526.87% YoY), but net income dropped to -$2,904,000 (down -34.28% YoY). EPS fell to -0.8 (down -91.08% YoY), and gross margin slightly decreased to 97.14% (down -2.86% YoY).
Maxim has lowered the price target from $10 to $6 while maintaining a Buy rating. The adjustment reflects share dilution despite positive clinical developments.
